Oruka Therapeutics, Inc. (ORKA) is a Healthcare · Biotechnology company listed on NASDAQ. Price $96.02 (-1.75%), Market cap $3.66B, 52-week low–high $10.90 ~ $76.39.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park
Financial statements, price targets, institutional (13F) holdings and related news for Oruka Therapeutics, Inc. are updated in real time on BlackAll Trade.
Oruka Therapeutics, Inc. trades at $96.02 (-1.75%). Real-time quotes and charts are available on BlackAll Trade.
Oruka Therapeutics, Inc. has a market cap of about $3.66B.
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indi